Global economic uncertainty and downgraded growth forecasts due to geopolitical conflicts, such as the Middle East conflict, can reduce investor appetite for early-stage biotechnology companies like Aditxt, impacting its ability to secure capital.

Changes or increased clarity in cryptocurrency regulation (e.g., CLARITY Act) could significantly affect Aditxt's 'bitXbio™ strategy' and 'Planned Digital Asset Treasury,' which aim to link public markets, digital assets, and life sciences.

The highly capital-intensive nature of biotechnology R&D, coupled with a challenging funding environment and the company's stated 'substantial doubt about its ability to continue as a going concern' with insufficient cash to fund operations, makes access to capital a critical macro factor.